Leica Biosystems, part of Danaher, agreed to buy Statlab Medical Products to broaden Danaher’s diagnostics and anatomical pathology portfolio with additional consumables and instruments. The deal terms were not disclosed. RBC Capital Markets analyst Dan Leonard estimated the acquisition could exceed $1 billion, underscoring how pathology workflows and instrument-adjacent consumables remain central to med-tech consolidation. The transaction also aligns with continued investment in integrated pathology testing platforms.